AnatomyDiseasesChemicals and Drugs
Apolipoprotein C-IApolipoproteins CApolipoprotein C-IIILipoproteins, VLDLTriglyceridesApolipoprotein A-INK Cell Lectin-Like Receptor Subfamily AReceptors, NK Cell Lectin-LikeApolipoproteins EApolipoprotein B-100Antigens, LyApolipoproteins BApolipoprotein E4Apolipoprotein E3Apolipoprotein A-IIApolipoproteinsApolipoprotein C-IIApolipoproteins AApolipoprotein B-48Apolipoprotein E2Lipoproteins, HDLApoprotein(a)CholesterolLipoproteinsLipoprotein(a)Apolipoproteins DLipoproteins, LDLLipidsReceptors, LDLAtherosclerosisCholesterol, HDLArteriosclerosisLiverPhosphatidylcholine-Sterol O-Acyltransferase

Genetic associations in diabetic nephropathy: a meta-analysis. (57/107)

 (+info)

Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease. (58/107)

 (+info)

Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. (59/107)

 (+info)

Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet. (60/107)

 (+info)

Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. (61/107)

 (+info)

Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. (62/107)

 (+info)

A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. (63/107)

 (+info)

Apolipoprotein C-I binds more strongly to phospholipid/triolein/water than triolein/water interfaces: a possible model for inhibiting cholesterol ester transfer protein activity and triacylglycerol-rich lipoprotein uptake. (64/107)

 (+info)